The Weekly BluRB — November 25th, 2025
We’re back with the Weekly BluRB. This Thanksgiving week, we delve into Nvidia’s earnings call, the United Kingdom’s major budget annoucement, and unpack the near-ban on the hemp industry. Continue Reading
We’re back with the Weekly BluRB. This Thanksgiving week, we delve into Nvidia’s earnings call, the United Kingdom’s major budget annoucement, and unpack the near-ban on the hemp industry. Continue Reading
The more matcha and boba shops open, the more each one struggles to survive. This oversaturation reflects more than just student demand, but a deeper set of economic, cultural, and aesthetic forces reshaping consumption habits and business survival in Berkeley. Read about it here.Continue Reading
We’re back with the Weekly BluRB! This week, we take a look at the yield curve and explore President Trump’s beef bailout. Meanwhile, President Xi Jinping plays chess with the White House, while Sudan’s crisis hits disastrous levels. Continue Reading
When will the government shutdown end? That’s the question on everyone’s mind. This week, we also explore China’s gold strategy, unpack Russian oil sanctions, and examine the state of American healthcare. Continue Reading
Find out how artificial intelligence is being utilized in relation to job automation and transforming current marketing roles. AI’s capabilities leave it undeniable that jobs will be lost, particularly low-skilled ones, but some leaders still advocate for positive outcomes if employees can find a way to work alongside the technology. As companies like Klarna crack down on current workers, this transition will need to occur sooner rather than later.Continue Reading
The US and Australia cut news deals while France and the UK are having a gloomy October. In our Story of the Week, diamonds might not be forever. Continue Reading
When you pick up medication at the drugstore, intuitively you might think that the cost of the drug is what you’re paying for. But you are not merely paying for the R&D and manufacturing costs; there is a complex system of middlemen that hike up the price of virtually every drug in the US market.Continue Reading
As China and the US go head-to-head in an escalating tariff battle, the US government shutdown adds fuel to the fire. OpenAI was valued at $500 billion, and pharmaceutical giant AstraZeneca struck a major deal with the White House. Meanwhile, India’s been focused on trade.Continue Reading
What makes US healthcare so expensive? Our neighbor in the north may serve some answers. While Canada and the US share similar backgrounds in culture, language, and economies, Canada’s universal healthcare system cuts healthcare prices in half compared to the US, and still outperforms the US in life expectancy and overall health.Continue Reading
In a polarizing world, we analyze whether international organizations will stand the test of time. As countries shift to nearshoring and quantitative barriers to trade, the fate of the WTO and its influence hangs in the balance.Continue Reading
We are a student group acting independently of the University of California. All information on this website is published in good faith and for general information purposes only. Business Review at Berkeley does not make any warranties about the completeness, reliability and/or accuracy of this information. The Editorials section features views of the individual authors and do not reflect the position of our organization as a whole or of the greater UC Berkeley community. No article or portion of an article should be construed as providing financial, legal, or political advice. Any action you take upon the information you find on this website is strictly at your own risk. Business Review at Berkeley will not be liable for any losses and/or damages in connection with the use of our website.
Designed using Unos Premium. Powered by WordPress.